Jamie Carr Columnist

Big pharma has repeatedly taken it in the neck over the years from commentators who appear outraged that the giants are so cold-hearted as to expect to make a profit from the medicines that they invest billions in to develop.

Clearly the rational answer is that without the chance of profit during the years of a drug’s patent protection, there will be no incentive to invest in R&D, and the production line of medical progress will come to a crashing halt.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now